Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last week:

‍Blogs :

Dr. Niemann discusses the investigation of ibrutinib plus venetoclax in CLL.

‍Dr. Alencar discusses the rationale for investigating BTK degraders in CLL.

‍Time-limited Venetoclax-Obinutuzumab therapy: rationale and supporting data.

‍Clinical insights and real-world evidence shaping treatment decisions and outcomes.

‍Dr. Ghia discusses potential future roles for ibrutinib plus venetoclax in CLL.

‍Also at MCH the News and Tweets never stop flowing!

Join Us at www.mycancerhaven.org

The Team @ MCH

Follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org.